“麝香保心丸”为临床治疗心肌缺血引起的冠心病心绞痛、心肌梗死的中药大品种，临床应用30余年，为国家基本药物。药理实验表明“麝香保心丸”具有促进血管生成作用，但是其促进血管生成的药效物质基础及作用机理不甚清楚。申请人前期在耶鲁大学的研究发现在炎症或缺血病理条件下RNA 稳定结合蛋白HuR对血管生成起到关键的调控作用，这种作用是通过在基因转录后调控血管生成因子mRNAs 稳定性，特别是调控VEGF mRNA 稳定性而促进相应基因的表达和蛋白释放增加，而促进血管生成的发生。本课题基于HuR调控血管生成的新靶点，根据“HuR-VEGF mRNA 稳定性-VEGF-血管生成”的调控机制，在已有的对“麝香保心丸”治疗冠心病的药效物质基础研究的基础上，深入系统地进行“麝香保心丸”促进血管生成活性成分及分子作用机制研究。该研究工作在国内外未见文献报道，具有创新意义。

"Shexiang Baoxin Pill" is the national basic drug and the large variety of traditional Chinese Medicine for the clinical treatment of angina coronary heart disease and myocardial infarction caused by myocardial ischemia with a history of more than 30 years. Pharmacological experiments showed that "Shexiang Baoxin Pill" can promote angiogenesis, but its pro-angiogenic pharmacodynamics substance and mechanism of angiogenesis are not very clear. The early study of applicant at the Yale University was found that the RNA-binding and -stabilizing protein HuR plays a critical role in the regulation of angiogenesis during inflammation or ischemic pathological conditions, which promote angiogenesis through posttranscriptional regulation of angiogenic factor-encoding mRNAs, special regulation of VEGF mRNA, to lead promote the corresponding gene expression and increase protein release, and promote the occurrence of angiogenesis. Based on the existing pharmacodynamics substance of "Shexiang Baoxin Pill" in the treatment of coronary heart disease, the project will study on the pro-angiogenic active components of "Shexiang Baoxin Pill" and molecular mechanism of angiogenesis based on HuR as a new target for the regulation of angiogenesis, according to the regulation mechanism of "HuR-VEGF mRNA stability -VEGF- angiogenesis". The research work of this project was not found in domestic and foreign literatures, has the innovation significance.